OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 11 of 19

12 Prescribing Obesity Medications Medications Approved for Short-Term Treatment of Obesity Drug How Taken Mechanism Phentermine and other sympathomimetics PO, up to three times daily for immediate release and daily for extended release Sympathomimetic amine; short-term labeled Medications Approved for Long-Term Treatment of Obesity (cont'd) Drug How Taken Main Side Effects Setmelanotide (POMC/PCSK1/LEPR def iciency; BBS; ≥2 y) Subcutaneous daily MC4R agonist Metreleptin (congenital/acquired generalized lipodystrophy with leptin def iciency) Subcutaneous daily Leptin analog Diazoxide choline (Prader-Willi hyperphagia) PO every 8-12 hours ATP-sensitive potassium channel (KATP) opener (appetite regulation)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026